Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study

    January 2018 in “ Figshare ”
    Nasser Almutairi, Tarek Nour, Nasser Haji Hussain

    Preprint — not peer reviewed. This was posted to a preprint server or data repository. It has not been through a journal's review process, and its findings may change or not hold up.

    Studysummary This study found that both ruxolitinib and tofacitinib were effective in promoting hair regrowth for patients with severe alopecia areata, with no significant difference in efficacy and relapse rate between them, and both were well tolerated throughout the treatment.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on karger.figshare.com →
    Discuss this study in the Community →

    Related research 3

    1. Treatment With Oral Janus Kinase Inhibitors in Adult Patients With Alopecia Areata: A Systematic Review and Meta-Analysis Journal of the American Academy of Dermatology · 2023
    2. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib PubMed · 2018
    3. Inhibiting Janus Kinases to Treat Alopecia Areata Nature medicine · 2014